Sci-Tech Montana: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sci-Tech Montana.

Press releases published on June 14, 2026

2 hours ago

Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

Indeterminate GlobeNewswire

4 hours ago

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control

Indeterminate GlobeNewswire

4 hours ago

Orbs Launches On-Chain Execution Infrastructure for Institutional Crypto Trading

Indeterminate GlobeNewswire

5 hours ago

Stake Launches its Referral Code SHIMA – 200% Bonus and 5% Cashback for New Users in 2026

Indeterminate GlobeNewswire

7 hours ago

Modat adds Passive DNS to its Platform Magnify, Connecting Every Signal in a Single Investigation Graph

Indeterminate GlobeNewswire

8 hours ago

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

Indeterminate GlobeNewswire

8 hours ago

Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)

Indeterminate GlobeNewswire

8 hours ago

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

Indeterminate GlobeNewswire

12 hours ago

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

Indeterminate GlobeNewswire

13 hours ago

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

Indeterminate GlobeNewswire

15 hours ago

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Indeterminate GlobeNewswire

Jun. 14, 2026

XM Announces Enhanced Trading Conditions and Opportunities for Global Traders - Featuring Partner Code 274PQ

Indeterminate GlobeNewswire